Roche Partnership
Announced April 2nd, 2004
Deal terms up to $276 million for E2F program
$15 million initial R&D payment
Significant annual R&D funding
Roche was granted option to in-license E2F compounds on completion of defined studies, in return for further payment
Royalties, milestones and co-promotion rights to ArQule